Safety of vedolizumab in the treatment of pregnant women with inflammatory bowel disease: a targeted literature review

BACKGROUND: Crohn’s disease (CD) and ulcerative colitis (UC) commonly affect women in their childbearing years. Vedolizumab (VDZ) is approved for treatment of moderate-to-severe CD and UC, but there is a knowledge gap regarding its use during pregnancy. This targeted literature review describes avai...

Descripción completa

Detalles Bibliográficos
Autores principales: Terjung, Birgit, Schmelz, Renate, Ehehalt, Robert, Klaus, Jochen, Knop, Jana, Schwind, Sabine, Wilke, Thomas, Stallmach, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580131/
https://www.ncbi.nlm.nih.gov/pubmed/33149762
http://dx.doi.org/10.1177/1756284820952592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580131/
https://www.ncbi.nlm.nih.gov/pubmed/33149762
http://dx.doi.org/10.1177/1756284820952592

Ejemplares similares